bjh

british journal of haematology

Volume 128, 2005 Pages 1–896

Issue 1, January-I 2005

Images in Haematology

1 **An unusual case of venous thromboembolism**
J. Motwani, P. E. Rose and W. Shatwell

2 **Myocardial biopsy and T2* magnetic resonance in heart failure due to thalassaemia**
M. A. Westwood, M. N. Sheppard, M. Awogbade, G. Ellis, A. D. Stephens and D. J. Pennell

Reviews

3 **A review of gene therapy for haematological disorders**
A. C. Nathwani, A. M. Davidoff and D. C. Linch

18 **Pathogenesis of acute myeloid leukaemia and inv(16)(p13;q22): a paradigm for understanding leukaemogenesis?**
J. T. Reilly

Haematological Malignancy

35 **Increased interferon gamma production by peripheral blood mononuclear cells in response to stimulation of overexpressed disease-specific 9-*O*-acetylated sialoglycoconjugates in children suffering from acute lymphoblastic leukaemia**
S. Ghosh, S. Bandyopadhyay, S. Pal, B. Das, D. K. Bhattacharya and C. Mandal

42 **Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients**
B. Arora, S. Sirhan, J. D. Hoyer, R. A. Mesa and A. Tefferi

49 **Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study**
M. S. Cairo, V. Davenport, O. Bessmertny, S. C. Goldman, S. L. Berg, S. G. Kreissman, J. Laver, V. Shen, R. Secola, C. van de Ven and G. H. Reaman

59 **Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch–Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial**
D. A. Breems, M. A. Boogaerts, A. W. Dekker, W. L. J. Van Putten, P. Sonneveld, P. C. Huijgens, J. Van der Lelie, E. Vellenga, A. Gratwohl, G. E. G. Verhoef, L. F. Verdonck and B. Löwenberg

Transplantation

66 **Impact of human herpesvirus-6 after haematopoietic stem cell transplantation**
M. Hentrich, D. Oruzio, G. Jäger, M. Schlemmer, M. Schleuning, X. Schiel, W. Hiddemann and H.-J. Kolb

73 **A class II-restricted cytotoxic T-cell clone recognizes a human minor histocompatibility antigen with a restricted tissue distribution**
P. A. Holloway, N. Kaldenhoven, H. M. Kok-Schoemaker, M. van Dijk, H. G. Otten, M. Tilanus, S. Postma, T. Mutis, H. M. Lokhorst and A. C. Bloem

Platelets, Haemostasis and Thrombosis

82 **Impact of O-linked glycosylation of the VWF-A1-domain flanking regions on platelet interaction**
J. S. am Esch II, S. C. Robson, W. T. Knoefel, C. F. Eisenberger, M. Peiper and X. Rogiers

91 **Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort**
P. E. Morange, D. A. Tregouet, C. Frere, N. Saut, L. Pellegrina, M. C. Alessi, S. Visvikis, L. Tiret and I. Juhan-Vague

100 **Relationship between ABO and Secretor genotype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals**
M. Schleef, E. Strobel, A. Dick, J. Frank, W. Schramm and M. Spannagl

Short report 108 **Factor-V expression in platelets from human megakaryocytic culture**
A. Giampaolo, F. Vulcano, G. Macioce, G. Mattia, A. Barca, L. Milazzo, C. Ciccarelli and H. J. Hassan

Red Cells and Iron

112 **Advanced glycation end-products in sickle cell anaemia**
S. S. Somjee, R. P. Warrier, J. L. Thomson, J. Ory-Ascani and J. M. Hempe

119 **Antioxidant deficit and enhanced susceptibility to oxidative damage in individuals with different forms of α-thalassaemia**
M.-l. Cheng, H.-y. Ho, H.-c. Tseng, C.-H. Lee, L.-y. Shih and D. T.-y. Chiu

Correspondence

128 **Human parvovirus B19-induced acquired pure amegakaryocytic thrombocytopenia**
J. Bhattacharyya, R. Kumar, S. Tyagi, J. Kishore, M. Mahapatra and V. P. Choudhry

130 **Erratum**

Announcement

131 **34th Annual Scientific Meeting: International Society for Experimental Hematology**

132 **Haematology Trainees Research Workshop**

Issue 2, January-II 2005

Images in Haematology

133 **Heavy bone marrow involvement with metastatic Merkel cell tumour in an immunosuppressed renal transplant recipient**
K. L. Morris, B. Williams and G. A. Kennedy

134 **Combined central retinal artery and vein occlusions as the presenting signs of ocular relapse in acute lymphoblastic leukaemia**
W.-M. Chan, D. T. L. Liu and D. S. C. Lam

Reviews

135 **Adenovirus as an emerging pathogen in immunocompromised patients**
A. M. Leen and C. M. Rooney

145 **Stem cell transplantation for chronic lymphocytic leukaemia**
S. Paneesha and D. W. Milligan

153 **The role of allogeneic transplantation in non-Hodgkin's lymphoma**
K. S. Peggs, S. Mackinnon and D. C. Linch

Haematological Malignancy

169 **Expression of functional interleukin-21 receptor on adult T-cell leukaemia cells**
M. Ueda, K. Imada, A. Imura, H. Koga, M. Hishizawa and T. Uchiyama

177 **Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma**
A. Korfel, P. Martus, M. R. Nowrousian, D. K. Hossfeld, H. Kirchen, J. Brücher, M. Stelljes, J. Birkmann, C. Peschel, R. Pasold, L. Fischer, K. Jahnke and E. Thiel for the German Primary Central Nervous System Lymphoma Study Group (G-PCNSL-SG)

184 **Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies**
G. E. de Greef, W. L. J. van Putten, M. Boogaerts, P. C. Huijgens, L. F. Verdonck, E. Vellenga, M. Theobald, E. Jacky, B. Löwenberg on behalf of The Dutch–Belgian Hemato–Oncology Co-operative Group HOVON and The Swiss Group for Clinical Cancer Research SAAK

192 **Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application**
T. Hayashi, T. Hideshima, M. Akiyama, K. Podar, H. Yasui, N. Raje, S. Kumar, D. Chauhan, S. P. Treon, P. Richardson and K. C. Anderson

204 **Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes**
P. Musto, F. Lanza, E. Balleari, A. Grossi, A. Falcone, G. Sanpaolo, C. Bodenizza, P. R. Scalzulli, A. La Sala, D. Campioni, R. Ghio, N. Cascavilla and A. M. Carella

210 **Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival**
N. F. Andersen, T. Standal, J. L. Nielsen, L. Heickendorff, M. Borset, F. B. Sørensen and N. Abildgaard

Short reports

218 **Increased AF1q gene expression in high-risk myelodysplastic syndrome**
W. Tse, H. J. Deeg, D. Stirewalt, F. R. Appelbaum, J. Radich and T. Gooley

221 **Presence of anti-kinectin and anti-PMS1 antibodies in Japanese aplastic anaemia patients**
N. Hirano, M. O. Butler, E. C. Guinan, L. M. Nadler and S. Kojima

Transplantation

224 **The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein–Barr virus reactivation after allogeneic haematopoietic stem cell transplantation**
S. Cesaro, A. Murrone, C. Mengoli, M. Pillon, M. A. Biasolo, E. Calore, G. Tridello, S. Varotto, R. Alaggio, L. Zanesco, G. Palù and C. Messina

234 **High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia**
F. Ferrara, S. Palmieri, M. De Simone, M. Sagristani, A. Viola, B. Pocali, A. Fasanaro and G. Mele

Platelets, Haemostasis and Thrombosis

242 **Patient self-testing is a reliable and acceptable alternative to laboratory INR monitoring**
C. Gardiner, K. Williams, I. J. Mackie, S. J. Machin and H. Cohen

248 **R255h amino acid substitution of protein Z identified in patients with factor V Leiden mutation**
B. Kemkes-Matthes, K. J. Matthes, M. Souri, S. Koseki-Kuno and A. Ichinose

Haemopoiesis and Leucocytes

253 **Sensitivity of adult T-cell leukaemia lymphoma cells to tumour necrosis factor-related apoptosis-inducing ligand**
H. Hasegawa, Y. Yamada, H. Harasawa, T. Tsuji, K. Murata, K. Sugahara, K. Tsuruda, S. Ikeda, Y. Imaizumi, M. Tomonaga, M. Masuda, N. Takasu and S. Kamihira

Red Cells and Iron

266 **Association of single nucleotide polymorphisms in *klotho* with priapism in sickle cell anaemia**
V. G. Nolan, C. Baldwin, Q. Ma, D. F. Wyszynski, Y. Amirault, J. J. Farrell, A. Bisbee, S. H. Embury, L. A. Farrer and M. H. Steinberg

Issue 3, February-I 2005

Images in Haematology

273 **Essential thrombocythaemia causing massive intra-abdominal thrombosis**
F. S. Taccone and W. Feremans

274 **Atypical haemolytic–uraemic syndrome at the onset of acute promyelocytic leukaemia**
A. Candoni, S. Pizzolitto, G. Boscutti and R. Fanin

Reviews

275 **Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia**
M. A. Elliott and A. Tefferi

291 **Management of thrombosis in cancer: primary prevention and secondary prophylaxis**
A. Y. Y. Lee

Historical Review

303 **The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review**
D. Ribatti

Haematological Malignancy

310 **Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against $CD33^+$ acute lymphoblastic leukaemias *in vitro* and *in vivo***
J. Golay, N. Di Gaetano, D. Amico, E. Cittera, A. M. Barbui, R. Giavazzi, A. Biondi, A. Rambaldi and M. Introna

318 **Development of a human acute myeloid leukaemia screening panel and consequent identification of novel gene mutation in *FLT3* and *CCND3***
M. L. Smith, R. Arch, L.-L. Smith, N. Bainton, M. Neat, C. Taylor, D. Bonnet, J. D. Cavenagh, T. A. Lister and J. Fitzgibbon

324 ***MDR1* and *MRP1* gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia**
M. Schaich, S. Soucek, C. Thiede, G. Ehninger and T. Illmer on behalf of the SHG AML96 Study Group

333 **The NFATc1 transcription factor is widely expressed in white cells and translocates from the cytoplasm to the nucleus in a subset of human lymphomas**
T. Marafiot, M. Pozzobon, M.-L. Hansmann, R. Ventura, S. A. Pileri, H. Roberton, S. Gesk, P. Gaulard, T. F. E. Barth, M. Q. Du, L. Leoncini, P. Möller, Y. Natkunam, R. Siebert and D. Y. Mason

343 **Preclinical studies on NSC290205 aza-steroid alkylator activity in combination with adriamycin against lymphoid leukaemia**
D. T. P. Trafalis, D. Tsavdaridis, C. Camoutsis, V. Karayiani, D. Mourelatos, E. Chrysogelou, P. Dalezis, A. Athanassiou, G. A. Pangalis and A. Papageorgiou

Transplantation

351 **Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation**
B. R. Dey, S. McAfee, C. Colby, K. Cieply, M. Caron, S. Saidman, F. Preffer, J. Shaffer, N. Tarbell, R. Sackstein, D. Sachs, M. Sykes and T. R. Spitzer

Platelets, Haemostasis and Thrombosis

360 **First description of somatic mosaicism in *MYH9* disorders**
S. Kunishima, T. Matsushita, T. Yoshihara, Y. Nakase, K. Yokoi, M. Hamaguchi and H. Saito

366 **Antiphospholipid antibodies in immune thrombocytopenic purpura tend to emerge in exacerbation and decline in remission**
C. J. Bidot, W. Jy, L. L. Horstman, E. R. Ahn, J. J. Jimenez, M. Yaniz, G. Lander and Y. S. Ahn

373 **Thrombotic thrombocytopenic purpura in patients with retroviral infection is highly responsive to plasma infusion therapy**
N. Novitzky, J. Thomson, L. Abrahams, C. du Toit and A. McDonald

380 **Severe FVII deficiency caused by a new point mutation combined with a previously undetected gene deletion**
J. Hewitt, J. N. M. Ballard, T. N. Nelson, V. C. Smith, T. A. M. Griffiths, S. Pritchard, J. K. Wu, L. D. Wadsworth, B. Casey and R. T. A. MacGillivray

Short reports

386 **Factor V Leiden, prothrombin 20210A and the risk of venous thrombosis among cancer patients**
M. Kennedy, A. C. M. Andreescu, M. S. Greenblatt, H. Jiang, C. A. Thomas, L. Chassereau, C. Wong, P. Durda and M. Cushman

389 **Tolerance to intravenous heparin in patients with delayed-type hypersensitivity to heparins: a prospective study**
Z. Gaigl, P. Pfeuffer, P. Raith, E.-B. Bröcker and A. Trautmann

Transfusion

393 **Pre-transfusion management of children with severe malarial anaemia: a randomised controlled trial of intravascular volume expansion**
K. Maitland, A. Pamba, M. English, N. Peshu, M. Levin, K. Marsh and C. R. J. C. Newton

401 **Inactivation of parvovirus B19 by liquid heating incorporated in the manufacturing process of human intravenous immunoglobulin preparations**
M. Yunoki, T. Urayama, M. Tsujikawa, Y. Sasaki, S. Abe, K. Takechi and K. Ikuta

Correspondence

405 **Serum free light chains for monitoring multiple myeloma**
J. Tate, P. Mollee and D. Gill

406 **Response to: Serum free light chains for monitoring multiple myeloma**
G. P. Mead, H. Carr-Smith, M. T. Drayson, G. T. Morgan and A. J. Child

407 **The co-expression of *PML/RARα* and *AML1/ETO* fusion genes is associated with ATRA resistance**
R. S. Abreu e Lima, M. R. Baruffi, A. S. G. de Lima, F. M. de Oliveira, L. L. de Figueiredo-Pontes, L. G. Tone, S. R. Rogatto, R. P. Falcão, M. de L. L. F. Chauffaille and E. M. Rego

Book Review

410 **Apoptosis Methods and Protocols**
P. D. Allen

Issue 4, February-II 2005

Images in Haematology

411 **Pneumonia in acute leukaemia: blossoming culprits**
L. Potenza, G. Riva, M. Luppi and G. Torelli

412 **Crystal-storing histiocytosis in a patient with IgGκ multiple myeloma**
E. Tholouli, M. Krebs, R. Reeve and J. B. Houghton

Reviews

413 **Lysosomal storage disorders**
A. Vellodi

432 **Haemopoietic stem cell transplantation in autoimmune diseases: a European perspective**
R. E. Hough, J. A. Snowden and N. M. Wulffraat

Haematological Malignancy

460 **Unique gene expression and clinical characteristics are associated with the 11q23 deletion in chronic lymphocytic leukaemia**
J. D. Dickinson, L. M. Smith, W. G. Sanger, G. Zhou, P. Townley, J. C. Lynch, Z. S. Pavletic, P. J. Bierman and S. S. Joshi

472 **Differential control of G_0 programme in chronic lymphocytic leukaemia: a novel prognostic factor**
A. V. Danilov, A. K. Klein, H. J. Lee, D. V. Baez and B. T. Huber

482 **Significance of the CC chemokine RANTES in patients with haematological malignancy: results from a prospective observational study**
M. Ellis, B. al-Ramadi, U. Hedström, C. Frampton, H. Alizadeh and J. Kristensen

Short reports

490 **Human leucocyte antigen class I and killer immunoglobulin-like receptor expression patterns in T-cell large granular lymphocyte leukaemia**
G. S. Nowakowski, W. G. Morice, R. L. Phyliky, C.-Y. Li and A. Tefferi

493 **Effect of IL-6 promoter polymorphism on incidence and outcome in Hodgkin's lymphoma**
P. Cordano, A. Lake, L. Shield, G. M. Taylor, F. E. Alexander, P. R. A. Taylor, J. White and R. F. Jarrett

Transplantation

496 **Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning – evidence for a superior outcome using melphalan combined with total body irradiation**
H. M. Hunter, K. Peggs, R. Powles, A. Rahemtulla, P. Mahendra, J. Cavenagh, T. Littlewood, M. Potter, A. Hunter, A. Pagliuca, C. D. Williams, G. Cook, K. Towlson, D. I. Marks and N. H. Russell on behalf of the Clinical Trials Committee of the British Society of Blood and Marrow Transplantation (BSBMT)

503 **Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation**
T. Feuchtinger, J. Lücke, K. Hamprecht, C. Richard, R. Handgretinger, M. Schumm, J. Greil, T. Bock, D. Niethammer and P. Lang

Short report 510 **Less than half of patients aged 65 years or under with myeloma proceed to transplantation: results of a two region population-based survey**
T. C. M. Morris, M. Velangi, G. Jackson, D. I. Marks and L. Ranaghan

Platelets, Haemostasis and Thrombosis

513 **Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism**
N. J. G. M. Veeger, M. Piersma-Wichers, J. G. P. Tijssen, H. L. Hillege and J. van der Meer

520 **Accuracy of platelet counting haematology analysers in severe thrombocytopenia and potential impact on platelet transfusion**
H. C. Segal, C. Briggs, S. Kunka, A. Casbard, P. Harrison, S. J. Machin and M. F. Murphy

526 **Prediction of haemorrhage in the early stage of acute myeloid leukaemia by flow cytometric analysis of platelet function**
E. B. Leinoe, M. H. Hoffmann, E. Kjaersgaard, J. D. Nielsen, O. J. Bergmann, T. W. Klausen and H. E. Johnsen

533 **Platelet glycoprotein Ib alpha polymorphisms affect the interaction with von Willebrand factor under flow conditions**
Y. Matsubara, M. Murata, T. Hayashi, K. Suzuki, Y. Okamura, M. Handa, H. Ishihara, T. Shibano and Y. Ikeda

Haemopoiesis and Leucocytes

540 **Induction of CCAAT/enhancer binding protein-δ by cytokinins, but not by retinoic acid, during granulocytic differentiation of human myeloid leukaemia cells**
Y. Ishii, T. Kasukabe and Y. Honma

Short report 548 **GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder**
E. Carpenter, V. Valverde-Garduno, A. Sternberg, C. Mitchell, I. Roberts, P. Vyas and A. Vora

Red Cells and Iron

552 **5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells**
O. Abdulmalik, M. K. Safo, Q. Chen, J. Yang, C. Brugnara, K. Ohene-Frempong, D. J. Abraham and T. Asakura

562 **The effect of hypoxia and stem cell source on haemoglobin switching**
A. D. Narayan, A. Ersek, T. A. Campbell, D. M. Colón, J. S. Pixley and E. D. Zanjani

571 **Childhood paroxysmal nocturnal haemoglobinuria (PNH), a report of 11 cases in the Netherlands**
M. M. van den Heuvel-Eibrink, R. G. M. Bredius, M. L. te Winkel, R. Tamminga, J. de Kraker, A. Y. N. Schouten-van Meeteren, M. Bruin and E. T. Korthof

Correspondence

578 **Poor performance of galactomannan and mannan sandwich enzyme-linked immunosorbent assays in the diagnosis of invasive fungal infection**
E. K. Allan, N. E. Jordanides, L. A. McLintock, M. Copland, M. Devaney, K. Stewart, A. N. Parker, P. R. E. Johnson, T. L. Holyoake and B. L. Jones

580 **Errata**

Issue 5, March-I 2005

Images in Haematology

581 **Bilateral optic disc oedema as the initial manifestation of leukaemic relapse**
A. Minamoto, J. Uka, J. Takenaka, H. K. Mishima and S. Nishimura

582 **Pohl-Pinkus constrictions of hair following chemotherapy for Hodgkin's disease**
P. J. Williamson and D. de Berker

Reviews

583 **Modern management of myelofibrosis**
F. Cervantes

593 **Low molecular weight heparin in pregnancy: current issues**
I. Greer and B. J. Hunt

Haematological Malignancy

602 **Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzyme**
J. Krauss, M. A. E. Arndt, B. K. Vu, D. L. Newton and S. M. Rybak

610 **Association of *NAT* and *GST* polymorphisms with non-Hodgkin's lymphoma: a population-based case–control study**
B. C.-H. Chiu, C. Kolar, S. M. Gapstur, T. Lawson, J. R. Anderson and D. D. Weisenburger

616 **Low-grade primary central nervous system lymphoma in immunocompetent patients**
K. Jahnke, E. Thiel, A. Schilling, U. Herrlinger, M. Weller, S. E. Coupland, U. Krümpelmann, H. Stein and A. Korfel

625 **Activity of sirolimus in patients with myelodysplastic syndrome – results of a pilot study**
U. Platzbecker, M. Haase, R. Herbst, A. Hänel, K. Voigtmann, C. H. Thiede, B. Mohr, E. Schleyer, T. Leopold, M. Orth, M. Hänel, G. Ehninger and M. Bornhäuser

631 **Toxicity in standard melphalan–prednisone therapy among myeloma patients with renal failure – a retrospective analysis and recommendations for dose adjustment**
K. Carlson, M. Hjorth and L. M. Knudsen for The Nordic Myeloma Study Group

636 **Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance *in vivo***
P. Zhou, N. Kalakonda and R. L. Comenzo

Short report 645 **Pregnancy improves neutropenia in T-cell large granular lymphocyte leukaemia**
N. Osuji, E. Matutes, C. Dearden and D. Catovsky

Transplantation

649 **Children with myelodysplastic syndrome (MDS) and increasing mixed chimaerism after allogeneic stem cell transplantation have a poor outcome which can be improved by pre-emptive immunotherapy**
P. Bader, C. Niemeyer, A. Willasch, H. Kreyenberg, B. Strahm, B. Kremens, B. Gruhn, D. Dilloo, J. Vormoor, P. Lang, D. Niethammer, T. Klingebiel and J. F. Beck

659 **Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning**
J. P. Panse, S. Heimfeld, K. A. Guthrie, M. B. Maris, D. G. Maloney, B. B. Baril, M.-T. Little, T. R. Chauncey, B. E. Storer, R. Storb and B. M. Sandmaier

668 **Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation**
L. M. Griffith, J. P. McCoy Jr, C. D. Bolan, D. F. Stroncek, A. C. Pickett, G. F. Linton, A. Lundqvist, R. Srinivasan, S. F. Leitman and R. W. Childs

676 **Impact of chimaerism analysis and kinetics on allogeneic haematopoietic stem cell transplantation outcome after conventional and reduced-intensity conditioning regimens**
A.-S. Michallet, S. Fürst, Q. H. Le, V. Dubois, A. Praire, F. Nicolini, X. Thomas, H. Rafii, L. Gebuhrer and M. Michallet

690 **Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis**
N. Kröger, T. Zabelina, H. Schieder, J. Panse, F. Ayuk, N. Stute, N. Fehse, O. Waschke, B. Fehse, H. M. Kvasnicka, J. Thiele and A. Zander

Platelets, Haemostasis and Thrombosis

698 **Platelet size deviation width, platelet large cell ratio, and mean platelet volume have sufficient sensitivity and specificity in the diagnosis of immune thrombocytopenia**
K. Kaito, H. Otsubo, N. Usui, M. Yoshida, J. Tanno, E. Kurihara, K. Matsumoto, R. Hirata, K. Domitsu and M. Kobayashi

703 **Difference in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III. Results from a family cohort study to assess the clinical impact of a laboratory test-based classification**
J.-L. P. Brouwer, N. J. G. M. Veeger, W. van der Schaaf, H. C. Kluin-Nelemans and J. van der Meer

Haemopoiesis and Leucocytes

711 **Autocrine secretion of osteopontin results in degradation of IκB in Bcr-Abl-expressing cells**
S. Vejda, K. Piwocka, S. L. McKenna and T. G. Cotter

Red Cells and Iron

722 **Heterogeneity of the εγδβ-thalassaemias: characterization of three novel English deletions**
H. Rooks, J. Bergounioux, L. Game, J. P. Close, C. Osborne, S. Best, T. Senior, S. Height, R. Thompson, N. Hadzic, P. Fraser, P. Bolton-Maggs and S. L. Thein

Correspondence

730 **Anti-inflammatory and angiostatic therapy in chemorefractory multisystem Langerhans' cell histiocytosis of adults**
A. Reichle, Th. Vogt, L. Kunz-Schughart, Th. Bretschneider, M. Bachthaler, K. Bross, S. Freund and R. Andreesen

732 **Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choice**
R. G. Owen and A. C. Rawstron

733 **Response to Owen and Rawstron**
F. W. Cremer, Y. Bouko, D. Samson, J. F. Apperley, K. Thielemans, B. Van Camp, A. Benner, H. Goblschmidt, M. Moos and M. H. C. Bakkus

734 **The Philadelphia translocation and pre-existing myeloproliferative disorders**
N. J. Curtin, P. J. Campbell and A. R. Green

Issue 6, March-II 2005

Images in Haematology

737 **Mixed pulmonary fungal infection with *Aspergillus fumigatus* and *Absidia corymbifera* in a patient with relapsed acute myeloid leukaemia**
L. A. McLintock, B. E. S. Gibson and B. L. Jones

738 **Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma**
A. M. Vannucchi, G. Ficarra, E. Antonioli and A. Bosi

Reviews

739 **Perforin and lymphohistiocytic proliferative disorders**
H. Katano and J. I. Cohen

751 **Defining stroke risk in children with sickle cell anaemia**
C. Hoppe

Haematological Malignancy

767 **c-Flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome**
M.-B. Valnet-Rabier, B. Challier, S. Thiebault, R. Angonin, G. Margueritte, C. Mougin, B. Kantelip, E. Deconinck, J.-Y. Cahn and T. Fest

774 **Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR**
G. Kerst, H. Kreyenberg, C. Roth, C. Well, K. Dietz, E. Coustan-Smith, D. Campana, E. Koscielniak, C. Niemeyer, P. G. Schlegel, I. Müller, D. Niethammer and P. Bader

783 **Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index C_i**
P. Staib, E. Staltmeier, K. Neurohr, O. Cornely, M. Reiser and T. Schinköthe

792 **Incidence and spectrum of non-Hodgkin lymphoma in Chinese migrants to British Columbia**
W. Y. Au, R. D. Gascoyne, R. D. Klasa, J. M. Connors, R. P. Gallagher, N. D. Le, F. Loong, C. K. Law and R. Liang

797 **Acute leukaemia in children with Down syndrome: a population-based Nordic study**
B. Zeller, G. Gustafsson, E. Forestier, J. Abrahamsson, N. Clausen, J. Heldrup, L. Hovi, G. Jonmundsson, S. O. Lie, A. Glomstein, H. Hasle on behalf of the Nordic Society of Paediatric Haematology and Oncology (NOPHO)

805 **Methylation status of the *p15* and *p16* genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia**
D. Hasegawa, A. Manabe, T. Kubota, H. Kawasaki, I. Hirose, Y. Ohtsuka, T. Tsuruta, Y. Ebihara, Y.-i. Goto, X. Y. Zhao, K. Sakashita, K. Koike, M. Isomura, S. Kojima, A. Hoshika, K. Tsuji and T. Nakahata

813 **Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma**
L. M. Pedersen, G. W. Jürgensen and H. E. Johnsen

Short report 820 **Characterizing CD43 expression in haematogones using multicolour flow cytometric analysis**
L. Tsao, A. I. Colovai, J.-G. Jiang, G. Bhagat and B. Alobeid

Transplantation

824 **Use of ^{18}F-FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions**
D. P. Hart, I. Avivi, K. J. Thomson, K. S. Peggs, E. C. Morris, A. H. Goldstone, D. C. Linch, P. J. Ell, J. B. Bomanji and S. Mackinnon

Platelets, Haemostasis and Thrombosis

830 **The prevalence of the cysteine1584 variant of von Willebrand factor is increased in type 1 von Willebrand disease: co-segregation with increased susceptibility to ADAMTS13 proteolysis but not clinical phenotype**
D. J. Bowen, P. W. Collins, W. Lester, A. M. Cumming, S. Keeney, P. Grundy, S. M. Enayat, P. H. B. Bolton-Maggs, D. M. Keeling, K. Khair, R. C. Tait, J. T. Wilde, K. J. Pasi and F. G. H. Hill on behalf of UK Haemophilia Centre Doctors' Organization

837 **Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies**
C. Pouplard, M. A. May, S. Regina, M. Marchand, J. Fusciardi and Y. Gruel

842 **An evaluation of rapid D-dimer assays for the exclusion of deep vein thrombosis**
C. Gardiner, C. Pennaneac'h, C. Walford, S. J. Machin and I. J. Mackie

Short report 849 **Interleukin 4, interleukin 6 and interleukin 10 polymorphisms in children with acute and chronic immune thrombocytopenic purpura**
K.-H. Wu, C.-T. Peng, T.-C. Li, L. Wan, C.-H. Tsai, S.-J. Lan, M.-C. Chang and F.-J. Tsai

Haemopoiesis and Leucocytes

853 **Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia**
W. Matsui, B. D. Smith, M. Vala, N. Beal, C. A. Huff, L. F. Diehl and R. J. Jones

863 **Activated T-lymphocytes with myelosuppressive properties in patients with chronic idiopathic neutropenia**
H. A. Papadaki, K. Stamatopoulos, A. Damianaki, C. Gemetzi, A. Anagnostopoulos, T. Papadaki, A. G. Eliopoulos and G. D. Eliopoulos

877 **Overexpression of the Doppel protein in acute myeloid leukaemias and myelodysplastic syndromes**
E. Travaglino, S. Comincini, C. Benatti, A. Azzalin, R. Nano, V. Rosti, L. Ferretti and R. Invernizzi

Correspondence

885 **A simple inhibitor screen is more sensitive than a Bethesda assay in monitoring for the development of inhibitors in haemophilia A and B**
D. Keeling, J. Beavis and K. Sukhu

885 **Pulmonary hypertension and thalidomide therapy in multiple myeloma**
Y. Hattori, M. Shimoda, S. Okamoto, T. Satoh, T. Kakimoto and Y. Ikeda

887 **Reply to Hattori *et al.*: Thalidomide and pulmonary hypertension. A causal or casual relationship?**
T. Younis and P. McCarthy

889 **Author Index**

893 **Keyword Index**